• Eli Lilly completed its acquisition of AtaiBeckley, a clinical-stage biopharmaceutical company focused on rapid-acting neuroplastogens for mental health conditions.
• The deal adds AtaiBeckley’s lead investigational program, BPL-003, being developed for treatment-resistant depression.
• AtaiBeckley shareholders cleared the transaction at a special meeting held before closing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609110902PR_NEWS_USPR_____DE45545) on September 11, 2026, and is solely responsible for the information contained therein.